TNX-1500

Monoclonal antibody

Earlyevidence

Evidence outlook

Mid-stage study registered, not yet recruiting

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Kidney Transplant Rejection
Phase 1 (1)
Other / comorbidity
NCT07473752 · Tonix Pharmaceuticals, Inc.
2023-07-18 – 2024-02-22 · Phase 1 First-in-human Study Involving Healthy Subjects
What this study did

Competitive landscape

Other CD40 ligand (CD40L / CD154) drugs

Frexalimab. Compare all 2 CD40 ligand (CD40L / CD154) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TNX-1500: this drugPhase 2Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary
Frexalimab
Phase 3(overall)
Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TNX-1500 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
September 2031 (1)
Phase 2Kidney Transplant RejectionNot yet recruiting
Est. primary completion 2031-09-01 · NCT07204080 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 February 2025Topline resultPositive topline results from Phase 1 trial of TNX-1500